Press Release / Media Release
Dear Sirs, We are pleased to enclose herewith our Press Release relating to announcement of financial results for the second quarter & first half ending September 30, 2017, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Board Meeting On Tuesday, November 14, 2017
1. This is to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, November 14, 2017 to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. 2. In view of the consideration of above, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from Friday, November 3, 2017 to Thursday, November 16, 2017 (both days inclusive).... Sun Pharma gets USFDA nod for generic drug to treat cardiac problems
As per IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017 Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to US FDA approval for generic Coreg CR, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Compliance Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended 30Th September, 2017
As per the requirements of Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find herewith the Compliance Certificate dated 23rd October, 2017 issued by Mr. Chintan Goswami, M/S. C. J Goswami & Associates, Practicing Company Secretaries, for the half year ended 30th September, 2017. Shareholding for the Period Ended September 30, 2017
Sun Pharmaceutical Industries Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2017. For more details, kindly Click here Pharma cos may post better results in Q2
Sun Pharma's top-line is likely to decline 15%, owing to increasing pressure on Taro's business Sun Pharma falls on raising stake in Ranbaxy Malaysia
For the quarter ended June 30, 2017, Sun Pharma reported total revenue at 1,802.52 crore and net loss stood at 1,290.99 crore. Updates on Acquisition
This is to inform you that one of the wholly owned subsidiaries of the Company has agreed to increase its shareholding in Ranbaxy Malaysia Sdn Bhd, Malaysia, by way of purchase of 666,985 shares of face value of MYR 1.00 each (equivalent to 8.3%) of Ranbaxy Malaysia Sdn Bhd. Updates
This is with reference to our letters dated April 21, 2017 to the stock exchanges providing our clarification on the US FDA inspection at the Company's Dadra facility wherein interalia we had indicated that we were then in the process of responding to the Form-483 observation letter issued by the US FDA post the inspection completed on April 13, 2017. We had further stated that if there are any material developments related to this inspection, we will promptly inform the stock exchanges....